Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Postoperative Pain, Hysterectomy
Interventions: IV Acetaminophen, IV Placebo 100 mL solution; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 27
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 21 more

Conditions: Head and Neck Cancer
Interventions: Xevinapant, IMRT, Placebo; Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 7 more

Conditions: Nasal Polyps, Chronic Rhinosinusitis
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 11
States / cities: Los Angeles, California • Roseville, California • Miami, Florida + 8 more

Conditions: PTSD
Interventions: Prolonged Exposure therapy, Hydrocortisone; Behavioral · Drug
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Placebo matching Olodaterol, Olodaterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 94
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more

Conditions: Muscular Dystrophies
Interventions: 3 mg/kg GSK2402968, 6 mg/kg GSK2402968, 9 mg/kg GSK2402968, 12 mg/kg GSK2402968, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 9 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Nausea
Interventions: aprepitant, dexamethasone, granisetron hydrochloride, palonosetron hydrochloride, prochlorperazine, placebo; Drug
Lead sponsor: Joseph Roscoe; Other
Eligibility: 18 Years and older
Enrollment: 1,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 16
States / cities: Mobile, Alabama • Decatur, Illinois • Wichita, Kansas + 13 more

Conditions: Exercise and Non-exercise Effect Upon Vitamins E and C
Interventions: Vitamin E and Vitamin C; Dietary Supplement
Lead sponsor: USDA Grand Forks Human Nutrition Research Center; Federal
Eligibility: 30 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles, Androgen Excess
Interventions: doxycycline, Sugar Pill; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Peanut Hypersensitivity
Interventions: Peanut OIT, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 6 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Influenza
Interventions: Peramivir, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 96
States / cities: Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more

Conditions: Alzheimer Disease
Interventions: DNL747, Placebo; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Dallas, Texas + 1 more

Conditions: Healthy, HIV
Interventions: Tenofovir disoproxil fumarate intravaginal ring, Placebo intravaginal ring (IVR); Drug
Lead sponsor: Marla Keller; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
Interventions: octreotide acetate, Placebo; Drug · Other
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 112
States / cities: Mobile, Alabama • Phoenix, Arizona • Chico, California + 89 more

Conditions: RSV Immunization
Interventions: RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 12 Months
Enrollment: 2,226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more

Conditions: Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 4,401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 152
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 149 more

Conditions: Benign Prostatic Hyperplasia
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Chicago, Illinois • Garden City, New York • New York, New York

Conditions: Atrial Fibrillation
Interventions: dapagliflozin, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Portland, Maine • Detroit, Michigan • Rochester, New York

Conditions: Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus, Pilonidal Cyst
Interventions: 1% Clascoterone, Vehicle Cream; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Icalcaprant, Placebo for Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more

Conditions: Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
Interventions: Pomalidomide, Prednisone, Placebo to pomalidomide, Placebo to prednisone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 6
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Pain Associated With Epidural Needle Insertion
Interventions: Synera(TM), Placebo patch; Drug · Other
Lead sponsor: IWK Health Centre; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: GSK5784283, Placebo, Standard of care; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Allergic Rhinitis, Allergic Conjunctivitis
Interventions: Fluticasone Propionate Nasal Spray, Saline Nasal Spray; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Search by objective public record fields.

Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

Cortisol Augmentation of a Psychological Treatment in Warfighters With Post Traumatic Stress Disorder (PTSD)

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

The Effects of Vitamin E and Vitamin C and Exercise

Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome

Oral Immunotherapy (OIT) for Peanut Allergy

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

A Study in Benign Prostatic Hyperplasia

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

Topical Anti-Androgens in Pilonidal Sinus Disease

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Synera™ for Epidural Needle Insertion

A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)

An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo